Neurofibromatosis Other
Solid Tumors Neurofibromatosis Other
APG-115-US-002: A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors (Open to MPNST)
- Ages: 12 Years and older
Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab. Part 2 is phase II design of APG-115 at recommended phase 2 dose (RP2D) in combination with pembrolizumab. APG-115-US-002: A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unre ...More
NF110: Phase 2 Clinical Trial of Crizotinib for Children and Adults with Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas (NF110)
- Ages: 6 Years and older
Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 c ...More
Contact Us
To learn more about available clinical trials related to solid tumors, contact us at cancer@cchmc.org or 513-636-2799.
Related Studies
- Retinoblastoma New Diagnosis
- Retinoblastoma Relapse / Refractory
- Neurofibromatosis Sarcoma New Diagnosis
- Neurofibromatosis Sarcoma Relapse / Refractory
- Neurofibromatosis NF2
- Plexiform Neurofibroma
- Neurofibromatosis OPG/Low Grade Glioma
- Melanoma New Diagnosis
- Melanoma Relapse / Refractory
- Germ Cell Tumor New Diagnosis
- Germ Cell Tumor Relapse / Refractory
- All Other Solid Tumors
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2022 Cincinnati Children's Hospital Medical Center. All rights reserved.
